Dengue fever is a febrile illness caused
by a single-stranded flavirius most commonly transmitted by the Aedes aegypti
mosquito. Dengue fever is one of the most prevalent arthropod-borne diseases
affecting humans. The severity of dengue fever ranges from asymptomatic cases,
to classic dengue fever, and to dengue hemorrhagic fever (DHF) or dengue shock
syndrome (DSS).
This report provides an overview of the
dengue fever risk factors and comorbidities, global and historical epidemiology
trends, and circulating serotypes (DENV-1, DENV-2, DENV-3, and DENV-4) in five
major markets (5MM) (Brazil, India, Mexico, Singapore, and Thailand). In
addition, this report includes a 10-year epidemiology forecast for the reported
laboratory-confirmed incident cases of dengue fever (including classic dengue
fever, DHF, and DSS) for the 5MM. The reported laboratory-confirmed incident
cases are segmented by sex and age (<1 year, 1 year, 2-14 years, 15-44
years, 45-64 years, and ≥65 years).
Publisher epidemiologists sourced
government-based publications for the forecast of reported laboratory-confirmed
dengue fever cases, including official national dengue reports, weekly
surveillance reports, and reportable disease databases.
Publisher epidemiologists forecast that
laboratory-confirmed dengue cases in the 5MM will increase from an annual
average of 304,608 cases from 2009-2013 to 339,104 cases in 2023 with an annual
growth rate (AGR) of 1.13%. Brazil will have almost half the number of reported
laboratory-confirmed dengue cases among the 5MM throughout the forecast period
(207,000 cases in 2023). Publisher epidemiologists believe that introductions
of new or long-dormant dengue serotypes would be a significant driver in
disease transmission in the 5MM during the next 10 years.
Know more about this
report at: http://mrr.cm/ZNq
No comments:
Post a Comment
Note: only a member of this blog may post a comment.